Monocytes and macrophages are the innate immune cells that make the EDIM blood test conceptually possible. EDIM — epitope detection in monocytes — does not look for tumour molecules floating free in plasma. It looks inside circulating monocytes for tumour-associated material those cells are presumed to have ingested in tissue.[1]

Why the cell biology matters to a patient. If the carrier cell is the measuring instrument, then anything that changes monocyte numbers, subsets, activation state or phagocytic appetite can change the number on the report — independently of whether cancer is present.

What this article covers. Monocyte subsets and lifespan, how macrophages take up tumour material, what tumour-associated macrophages actually do, and where the honest evidence limits of the EDIM concept sit. This is educational content about immune biology at VELAR Center in Bangkok, not a diagnostic claim.

Important framing

EDIM is investigational. It is not a stand-alone cancer diagnosis and does not replace guideline-recommended cancer screening, imaging, endoscopy or tissue pathology. A positive result does not establish cancer; a negative result does not exclude it.

Human blood monocyte subsets — classical, intermediate and non-classical monocytes relevant to EDIM cancer testing

What monocytes are and why the EDIM test uses them

Monocytes are short-lived circulating white blood cells that patrol tissue, ingest cellular debris, and differentiate into macrophages and dendritic cells. They are part of the innate immune system — the arm that responds without needing prior antigen-specific training.[8]

Human blood monocytes are conventionally divided into three populations by surface CD14 and CD16 expression: classical (CD14++CD16−), intermediate (CD14++CD16+) and non-classical (CD14+CD16++).[5] This nomenclature was standardised because different laboratories were using incompatible definitions — a detail that directly affects how any monocyte-based assay is gated and compared between centres.

The subsets are not interchangeable. Classical monocytes dominate numerically and are strongly phagocytic and inflammatory. Non-classical monocytes patrol the vascular endothelium. Intermediate monocytes sit between the two and are often expanded in inflammation.[6][7] EDIM protocols specifically target activated CD14/CD16-positive fractions, which is why monocyte subset shifts are a plausible source of assay variation.

Lifespan is short. Circulating monocytes persist for a limited period before entering tissue or dying, which means the blood compartment reflects a recent, rolling sample of immune activity rather than a long-term record. A monocyte-carried signal is therefore a snapshot, not a cumulative history.

How macrophages take up tumour material

Macrophages ingest dying cells and cellular fragments through phagocytosis, and that uptake is the presumed mechanism by which tumour-associated epitopes enter a monocyte. Tumours are metabolically stressed, proliferative and frequently necrotic, so they release substantial cellular debris into surrounding tissue.

Two candidate tumour-associated markers are measured in EDIM protocols: Apo10, an epitope of the DNaseX/apoptosis-related protein linked to disturbed apoptosis, and TKTL1, transketolase-like 1, associated with altered glucose metabolism.[1] TKTL1 is biologically interesting because aerobic glycolysis — the Warburg effect — is a recognised feature of proliferating cells, not a cancer-exclusive event.[14] TKTL1 expression has also been reported to vary with progression in colorectal cancer tissue.[15]

Deregulated metabolism and evasion of apoptosis are recognised hallmarks of cancer.[13] That makes both markers biologically rational targets. It does not make them specific: normal proliferating tissue, regenerating tissue and inflamed tissue share elements of the same biology.

Macrophages infiltrating a tumour and engulfing malignant cell debris — the biological basis of epitope detection in monocytes

Tumour-associated macrophages: allies and accomplices

Tumour-associated macrophages (TAMs) are among the most abundant immune cells inside many solid tumours, and they frequently support rather than suppress tumour growth.[9] They can promote angiogenesis, matrix remodelling, metastatic seeding and local immune suppression.[10]

Because of this, TAMs are an active drug-development target in oncology — through CSF1R blockade, recruitment inhibition, and reprogramming strategies.[11] Those programmes remain largely investigational, and results have been mixed.

Monocyte heterogeneity in cancer patients is well documented. Circulating monocyte phenotype and function are altered in malignancy, including changes in subset distribution and suppressive capacity.[12] This cuts two ways for a monocyte-based assay: it supports the premise that circulating monocytes carry tumour-related information, and it warns that the carrier population itself is disturbed in the very patients being tested.

Why inflammation and infection complicate the signal

Monocytes are recruited aggressively during infection and inflammation, which changes both their number and their state.[18] Any assay expressed as a proportion of activated monocytes has a denominator that moves.

Practical consequences worth discussing with a clinician before testing:

None of this makes the measurement meaningless. It means an isolated number, read without clinical context, is easy to over-interpret in either direction. Our related discussion of EDIM and inflammation-driven false positives covers this in clinical detail.

What the published EDIM evidence actually shows

The EDIM literature consists mainly of small, selected-population studies, not large prospective screening trials. Reported work includes a cohort in cholangiocellular, pancreatic and colorectal carcinoma,[2] a paediatric rhabdomyosarcoma liquid-biopsy application,[3] and a pilot study in childhood neuroblastoma.[4]

Case-control design inflates apparent accuracy. When a study compares known cancer patients with healthy controls, sensitivity and specificity usually look better than they will in an unselected population where disease prevalence is low. Reporting and quality frameworks exist precisely because of this — STARD for reporting diagnostic accuracy studies,[16] and QUADAS-2 for appraising risk of bias.[17]

Compare this with the trajectory of plasma-based liquid biopsy. ctDNA methods took years of analytical validation, standardisation and prospective work before clinical implementation was seriously discussed.[19] EDIM has not accumulated a comparable independent evidence base. Our EDIM versus liquid biopsy comparison sets the two side by side.

Evidence checkpoint

Biological plausibility is necessary but not sufficient. A mechanism can be coherent and a test can still fail to change outcomes. The questions that matter are: which population was studied, what was the reference standard, was the assay independently reproduced, and did testing improve a patient-relevant result?

How a monocyte-based result should be used in practice

Treat an EDIM result as one contextual data point inside a clinician-led assessment, never as a verdict. A responsible pathway looks like this:

  1. Establish the clinical question first. Symptoms, family history, risk factors and screening status determine what testing is appropriate.
  2. Complete guideline screening. Organ-specific programmes have outcome evidence behind them; a blood biomarker does not substitute for them.
  3. Record confounders. Recent infection, inflammation, medication and surgery should be documented before the sample is drawn.
  4. Interpret with the full laboratory report. Gating strategy, subset definitions and quality control affect the number — see our note on EDIM preparation and laboratory workflow.
  5. Escalate through conventional pathways only. Abnormal findings are investigated with imaging, endoscopy or pathology, directed by the appropriate specialist.

At VELAR Center in Bangkok, cellular and immune-biology testing is discussed as adjunctive information within a physician assessment. No biomarker offered here is presented as a cancer diagnosis.

From blood draw to number: where monocyte biology meets laboratory reality

A monocyte-based assay is only as stable as the cells it measures, and monocytes change quickly outside the body. Time from venepuncture to analysis, storage temperature, anticoagulant choice and handling all influence monocyte activation state. This is a general property of flow-cytometric immune phenotyping, not a criticism unique to EDIM.

Gating is an interpretive act. Deciding which events count as activated CD14/CD16-positive monocytes requires operator-defined boundaries. Standardised subset nomenclature exists precisely because inconsistent gating made results incomparable across laboratories.[5] When comparing two results from different providers, the gating strategy matters as much as the headline score.

Serial results are more informative than single ones — with caveats. A trend measured in the same laboratory, with the same protocol, under comparable clinical conditions, carries more interpretive weight than one isolated number. But a rising trend still requires conventional diagnostic work-up to mean anything clinically, and a falling trend does not confirm treatment success.

Questions worth asking before any monocyte-based test

Ask about population, protocol and consequence before you ask about the price. The following questions separate a considered decision from a purchase:

These questions apply to every emerging biomarker, not only EDIM. They are the same principles that shaped the slow, disciplined path ctDNA testing has taken toward clinical use.[19]

Does a routine monocyte count on a blood panel tell you anything?

A monocyte count on a standard complete blood count measures quantity, not cargo — it says nothing about tumour-associated epitopes. Monocytosis, an elevated monocyte count, has a long differential that includes chronic infection, recovery from acute infection, inflammatory disease, certain haematological disorders and some malignancies. It is a prompt for clinical thought, not a cancer signal.

The two measurements answer different questions. A CBC tells a clinician how many monocytes are circulating. A monocyte-based epitope assay claims to describe what a subset of those cells contains. Because monocyte biology in cancer patients is demonstrably altered in both number and phenotype,[12] reading either measurement in isolation risks the same error: attributing a general immune response to one specific cause.

Practical takeaway. If a routine panel shows an abnormal monocyte count, the correct next step is a clinical review of the whole picture — symptoms, history, other blood indices, examination — not a reflexive purchase of an investigational biomarker test.

Monocyte biology and NK cells: two different immune stories

Monocytes are sampling and presenting cells; natural killer cells are cytotoxic effectors. Monocyte-derived information underlies a diagnostic concept, whereas NK-cell biology underlies a therapeutic one. Both are innate immunity, but the clinical questions are unrelated — and the evidence bases are separate. Readers interested in the effector side can start with how NK cells recognise and kill cancer cells.

Frequently Asked Questions

What do monocytes have to do with a cancer blood test?

EDIM measures tumour-associated epitopes inside monocytes rather than in plasma, on the premise that these cells ingest tumour material in tissue and carry it into circulation.[1] The monocyte is the carrier, not the tumour.

Can inflammation cause an abnormal monocyte-based cancer test?

It plausibly can. Monocytes are recruited and activated during infection, injury and chronic inflammation, which changes both counts and subset distribution.[18] Clinical context is essential before acting on any single result.

Are Apo10 and TKTL1 cancer-specific?

No. Apo10 relates to disturbed apoptosis and TKTL1 to altered glucose metabolism — both are hallmarks of proliferating cells generally, not features unique to malignancy.[13][14]

Does a normal result mean I can skip screening?

No. Guideline-recommended screening — mammography, cervical screening, colorectal testing, low-dose lung CT where indicated — should continue regardless of any investigational blood biomarker result.

Why are tumour-associated macrophages described as harmful?

Because in many solid tumours they promote angiogenesis, tissue remodelling and local immune suppression rather than tumour clearance.[9][10] They are being actively studied as drug targets.[11]

How strong is the EDIM evidence base in 2026?

Limited. Published studies are small, mostly case-control, and concentrated in a few tumour types.[2][3][4] Large independent prospective validation in unselected populations has not been established.

Bottom line

The immune biology behind EDIM is real and reasonably well characterised: monocytes circulate, enter tissue, phagocytose debris, and become macrophages that interact intimately with tumours. That biology makes a monocyte-carried tumour signal conceptually plausible.

Plausible is not the same as validated. The same biology that could carry a tumour signal also responds to infection, injury, inflammation, medication and normal tissue turnover. Until large, independent, prospective studies in unselected populations demonstrate that monocyte-based testing changes patient outcomes, the conservative position stands: use it, if at all, as adjunctive information alongside — never instead of — guideline-recommended screening and clinician-directed diagnosis.

Medical disclaimer

This article is educational and does not constitute medical advice, diagnosis or treatment. Discuss any cancer-screening decision, symptom or test result with a qualified physician. EDIM and other biomarker assays discussed here are investigational and are not a substitute for guideline-recommended cancer screening or diagnostic evaluation.

References

  1. Coy J. EDIM-TKTL1/Apo10 Blood Test: An Innate Immune System Based Liquid Biopsy for the Early Detection, Characterization and Targeted Treatment of Cancer. International Journal of Molecular Sciences. 2017;18:878. doi:10.3390/ijms18040878 ↩
  2. Saman S, Stagno M, Warmann S, et al.. Biomarkers Apo10 and TKTL1: Epitope-detection in monocytes (EDIM) as a new diagnostic approach for cholangiocellular, pancreatic and colorectal carcinoma. Cancer Biomarkers. 2019;27:129-137. doi:10.3233/CBM-190414 ↩
  3. Urla C, Stagno MJ, Schmidt A, et al.. Epitope Detection in Monocytes (EDIM) As a New Method of Liquid Biopsy in Pediatric Rhabdomyosarcoma. Biomedicines. 2022;10:1812. doi:10.3390/biomedicines10081812 ↩
  4. Stagno MJ, Schmidt A, Bochem J, et al.. Epitope detection in monocytes (EDIM) for liquid biopsy including identification of GD2 in childhood neuroblastoma—a pilot study. British Journal of Cancer. 2022;127:1324-1331. doi:10.1038/s41416-022-01855-x ↩
  5. Ziegler-Heitbrock L, Ancuta P, Crowe S, et al.. Nomenclature of monocytes and dendritic cells in blood. Blood. 2010;116:e74-e80. doi:10.1182/blood-2010-02-258558 ↩
  6. Guilliams M, Mildner A, Yona S. Developmental and Functional Heterogeneity of Monocytes. Immunity. 2018;49:595-613. doi:10.1016/j.immuni.2018.10.005 ↩
  7. Jakubzick CV, Randolph GJ, Henson PM. Monocyte differentiation and antigen-presenting functions. Nature Reviews Immunology. 2017;17:349-362. doi:10.1038/nri.2017.28 ↩
  8. Ginhoux F, Jung S. Monocytes and macrophages: developmental pathways and tissue homeostasis. Nature Reviews Immunology. 2014;14:392-404. doi:10.1038/nri3671 ↩
  9. Mantovani A, Marchesi F, Malesci A, et al.. Tumour-associated macrophages as treatment targets in oncology. Nature Reviews Clinical Oncology. 2017;14:399-416. doi:10.1038/nrclinonc.2016.217 ↩
  10. Noy R, Pollard JW. Tumor-Associated Macrophages: From Mechanisms to Therapy. Immunity. 2014;41:49-61. doi:10.1016/j.immuni.2014.06.010 ↩
  11. Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nature Reviews Drug Discovery. 2018;17:887-904. doi:10.1038/nrd.2018.169 ↩
  12. Olingy CE, Dinh HQ, Hedrick CC. Monocyte heterogeneity and functions in cancer. Journal of Leukocyte Biology. 2019;106:309-322. doi:10.1002/JLB.4RI0818-311R ↩
  13. Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discovery. 2022;12:31-46. doi:10.1158/2159-8290.CD-21-1059 ↩
  14. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. Science. 2009;324:1029-1033. doi:10.1126/science.1160809 ↩
  15. Diaz-Moralli S, Tarrado-Castellarnau M, Alenda C, et al.. Transketolase-Like 1 Expression Is Modulated during Colorectal Cancer Progression and Metastasis Formation. PLoS ONE. 2011;6:e25323. doi:10.1371/journal.pone.0025323 ↩
  16. Bossuyt PM, Reitsma JB, Bruns DE, et al.. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015:h5527. doi:10.1136/bmj.h5527 ↩
  17. Whiting PF, Rutjes AW, Westwood ME, et al.. QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies. Annals of Internal Medicine. 2011;155:529-536. doi:10.7326/0003-4819-155-8-201110180-00009 ↩
  18. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nature Reviews Immunology. 2011;11:762-774. doi:10.1038/nri3070 ↩
  19. Wan JCM, Massie C, Garcia-Corbacho J, et al.. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nature Reviews Cancer. 2017;17:223-238. doi:10.1038/nrc.2017.7 ↩